FDA批准血液测试, 帮助排除有认知症状的病人患老年痴呆症。 FDA approves blood test to help rule out Alzheimer’s in patients with cognitive symptoms.

林业发展局批准了由Roche和Eli Lilly开发的Elecsys pTau181血液测试,以帮助在有认知症状的成年人中排除阿尔茨海默氏病。 The FDA has approved the Elecsys pTau181 blood test, developed by Roche and Eli Lilly, to help rule out Alzheimer’s disease in adults showing cognitive symptoms. 测试测量了与阿尔茨海默氏病有关的蛋白质,在对312名参与者进行的一项研究中,在识别无病者时显示准确度为97.9%。 The test measures a protein linked to Alzheimer’s and showed 97.9% accuracy in identifying those without the condition in a study of 312 participants. 它不是一个独立的诊断工具,而是更广泛的评价的一部分,负面结果表明有其他原因,积极结果促使进一步测试。 It is not a standalone diagnostic tool but part of a broader evaluation, with negative results suggesting alternative causes and positive results prompting further testing. 专家告诫不要因潜在的假阳性而过分依赖,并强调临床判断仍然至关重要。 Experts caution against overreliance due to potential false positives and stress that clinical judgment remains essential. 批准标志着在早期发现方面取得的进展,有可能减少对侵入性程序的需求,改善获得护理的机会。 The approval marks progress in early detection, potentially reducing the need for invasive procedures and improving access to care.